Meta-Analysis: Carfilzomib-Associated Cardiovascular Adverse Events

Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis – JAMA Oncology (link to abstract – $ for full-text)

Commentaries: Carfilzomib can lead to cardiovascular toxicity in multiple myeloma patients – eCancer News (free) AND Higher Rates of Cardiovascular Adverse Events in Patients with MM Treated With Carfilzomib – AJMC (free) AND Important CV Risk Seen With Carfilzomib in Multiple Myeloma – Medscape (free registration required)